$MCK (McKesson Corporation)

$MCK {{ '2015-07-02T15:41:22+0000' | timeago}} • SEC

$MCK FY15 10-K: As of March 31, 2015 gross profit was $11,411MM and gross margin was 6.37%, respectively. Gross profit and GM increased over last two years due to business acquisitions, higher buy margin and mix of business. Gross profit was impacted by higher LIFO-related inventory charges which were $337MM, $311MM & $13MM in 2015, 2014 and 2013.

$MCK {{ '2017-05-24T20:45:05+0000' | timeago}} • Announcement

The Board of Directors of $MCK declared a regular dividend of $0.28 per share on common stock. The dividend will be payable on July 3, 2017, to stockholders of record on June 5, 2017.

$MCK {{ '2017-05-18T22:30:24+0000' | timeago}} • Webcast

$MCK stated that on the buy side for generics, the company is seeing a deflation going forward. However, the company added that deflation is not a big factor that plays into the way its economics or P&L operates.

$MCK {{ '2017-05-18T21:05:10+0000' | timeago}} • Announcement

During 4Q17, $MCK's Distribution Solution revenues rose 5% YoY to $48.2Bil. Revenues of North America pharmaceutical distribution and services revenues were $40.6Bil, up 5%. International pharmaceutical distribution and services revenues were $6.1Bil and Medical-Surgical distribution and services revenues were $1.6Bil.

$MCK {{ '2017-05-18T21:01:30+0000' | timeago}} • Announcement

$MCK reported an increase in 4Q17 profit, due to a pre-tax gain of $3.9Bil related to the previously announced creation of the Change Healthcare joint venture. Net income rose to $3.6Bil, or $16.95 per share, compared to $431MM, or $1.97 per share during 4Q16. Revenues rose 4% YoY to $46.7Bil during the quarter.

$MCK {{ '2017-04-04T14:57:34+0000' | timeago}} • Announcement

$MCK completed the previously announced acquisition of CoverMyMeds LLC. CoverMyMeds is a player in electronic prior authorization (ePA) solutions.

$MCK {{ '2017-03-02T17:03:35+0000' | timeago}} • Announcement

$MCK lifted FY17 EPS from continuing operations guidance to $20.35-22.50 from $9.80-10.30, while lowering adjusted EPS outlook to $12.45-12.75 from $12.60-12.90. $MCK will record its share of a one-time, non-cash reduction to the carrying value of its deferred revenue balance. This will lower earnings in FY18 by about $140-170MM.

$MCK {{ '2017-03-02T16:59:04+0000' | timeago}} • Announcement

In 4Q17, $MCK expects to record a pre-tax gain of about $2.9-3.5Bil, which includes $1.25Bil in cash receipts, and associated non-cash income tax expense of about $0.5-0.8Bil, both of which will be excluded from adjusted earnings. As a result of net gain, $MCK will add about $10.70-12.35 in EPS from continuing operations.

$MCK {{ '2017-01-26T11:50:05+0000' | timeago}} • Announcement

$MCK's BoD declared a regular dividend of 28 cents per share on common stock. The dividend will be payable on April 3, 2017, to stockholders of record on March 1, 2017.

$MCK {{ '2017-01-25T23:00:05+0000' | timeago}} • Announcement

On Jan. 24, 2017 $MCK entered into an agreement to acquire CoverMyMeds for approx. $1.1Bil, or $0.9Bil net of incremental cash tax benefits. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the first half of FY18.

$MCK {{ '2017-01-25T22:57:39+0000' | timeago}} • Announcement

During 3Q17, $MCK's Distribution Solutions reported 5% growth in its revenues to $49.4MM. North America pharmaceutical distribution and services revenues rose 5% to $41.7Bil and International pharmaceutical distribution and services revenues were $6.2Bil for the quarter, up 3%.

$MCK {{ '2017-01-25T22:53:51+0000' | timeago}} • Announcement

$MCK reported flat 3Q17 earnings results. Net income during the quarter was $633MM compared to $634 during 3Q16. Diluted EPS rose 4.3% YoverY to $2.85 from $2.73 due to the lower weighted average common share. Revenues rose 5% YoverY to $50.1Bil. Excluding items, $MCK earned $3.05 per share.

$MCK {{ '2017-01-18T12:03:05+0000' | timeago}} • Announcement

$MCK finalized administrative and civil settlements to resolve U.S. Drug Enforcement Administration (DEA) and U.S. Department of Justice (DOJ) potential federal civil and administrative claims regarding its monitoring and reporting of suspicious controlled substance orders.

$MCK {{ '2016-12-29T12:00:14+0000' | timeago}} • Announcement

$MCK, which agreed to acquire Rexall Health for CAD2.9Bil in March 2016, closed that acquisition. Earlier, the company reached an agreement with the Competition Bureau of Canada for this acquisition and received approval under the Investment Canada Act. Also, $MCK appointed Domenic Pilla as CEO of McKesson Canada, effective Jan. 3, 2017.

$MCK {{ '2016-12-14T18:12:31+0000' | timeago}} • Announcement

$MCK said it signed a consent agreement with the Competition Bureau of Canada allowing it to proceed with the acquisition of Rexall Health. The transaction is expected to close as efficiently as possible subject to certain closing conditions.

$MCK {{ '2016-10-28T14:15:10+0000' | timeago}} • Announcement

$MCK's BoD declared a regular quarterly dividend of 28 cents per share on its common stock. The dividend will be payable on Jan. 2, 2017 to stockholders of record on Dec. 1, 2016.

$MCK {{ '2016-10-28T00:45:17+0000' | timeago}} • Webcast

In $MCK’s Technology Solutions segment, revenues were down 6% for 2Q17 to $680MM on a constant currency basis, driven by the anticipated decline in the hospital software business, partially offset by growth in other technology businesses.

$MCK {{ '2016-10-28T00:42:00+0000' | timeago}} • Webcast

In 2Q17, in $MCK’s Distribution Solutions segment, revenues grew 3% to $49.3Bil. North America pharmaceutical distribution and services revenues grew 2%  in constant currency. International pharmaceutical distribution and services revenues grew 12% in constant currency. Medical-Surgical revenues were up 4% in 2Q17.

$MCK {{ '2016-10-28T00:22:10+0000' | timeago}} • Webcast

$MCK expects to receive less compensation from branded price increases than originally anticipated in FY17. The company will monitor pricing activities throughout the year, especially in 4Q17, which is an important quarter for price increases. $MCK is engaging with its manufacturer partners to ensure it receives appropriate compensation.

$MCK {{ '2016-10-27T21:06:35+0000' | timeago}} • Webcast

$MCK expects 2017 GAAP earnings per diluted share from continuing operations to be $8.95 to $9.80. Excluding charges, earnings per share are expected to be $12.35 to $12.85.

$MCK {{ '2016-10-27T21:04:02+0000' | timeago}} • Webcast

Pharmaceutical distributor $MCK reported a 49% fall in its 2Q16 earnings per share that fell to $1.35, hurt by charges, but revenue rose 2% to $50Bil. The results included a non-cash, pre-tax goodwill impairment charge of $290MM, or $1.24, and pre-tax credits of $10MM, or 2 cents.

Recent Transcripts

ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
ORCL (Oracle Corporation)
Wednesday, June 21 2017 - 9:00pm
STRM (Streamline Health Solutions, Inc.)
Tuesday, June 13 2017 - 1:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
CSCO (Cisco Systems, Inc.)
Wednesday, May 17 2017 - 8:30pm
HMSY (HMS Holdings Corp.)
Wednesday, May 10 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
DOX (Amdocs Limited)
Tuesday, May 9 2017 - 9:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
HLF (Herbalife Ltd.)
Thursday, May 4 2017 - 9:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, May 4 2017 - 12:30pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, May 3 2017 - 9:00pm
HSKA (Heska Corporation)
Tuesday, May 2 2017 - 3:00pm
CAH (Cardinal Health, Inc.)
Monday, May 1 2017 - 12:30pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Friday, April 28 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm

AlphaGraphics you may like